CA1326439C - Formules d'hormone de croissance administrees par voie parenterale - Google Patents

Formules d'hormone de croissance administrees par voie parenterale

Info

Publication number: CA1326439C
Authority: CA; Canada
Prior art keywords: growth hormone; percent; formulation; cresol; human growth
Prior art date: 1987-11-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 566846

Other languages

English (en)

Inventor

Bradford Hunt Arthur

Michael Bornstein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-05

Filing date

1988-05-16

Publication date

1994-01-25

1988-05-16 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

1994-01-25 Application granted granted Critical

1994-01-25 Publication of CA1326439C publication Critical patent/CA1326439C/fr

2011-01-25 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 32
238000009472 formulation Methods 0.000 title claims abstract description 31
102000018997 Growth Hormone Human genes 0.000 title description 3
108010051696 Growth Hormone Proteins 0.000 title description 2
239000000122 growth hormone Substances 0.000 title description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 34
102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 27
108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 27
239000000854 Human Growth Hormone Substances 0.000 claims abstract description 27
235000011187 glycerol Nutrition 0.000 claims abstract description 17
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims abstract description 16
229940100630 metacresol Drugs 0.000 claims abstract description 14
229960005150 glycerol Drugs 0.000 claims abstract description 5
210000003205 muscle Anatomy 0.000 claims description 17
230000007794 irritation Effects 0.000 claims description 16
238000010255 intramuscular injection Methods 0.000 claims description 6
239000007927 intramuscular injection Substances 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000006201 parenteral dosage form Substances 0.000 claims 3
238000000034 method Methods 0.000 abstract description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
239000003085 diluting agent Substances 0.000 description 7
229940109239 creatinine Drugs 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
239000003814 drug Substances 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
239000002687 nonaqueous vehicle Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
102000000827 Anterior Pituitary Hormones Human genes 0.000 description 1
108010001897 Anterior Pituitary Hormones Proteins 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000003329 adenohypophysis hormone Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
238000004500 asepsis Methods 0.000 description 1
239000008228 bacteriostatic water for injection Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
230000003131 corticotrophic effect Effects 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
229940084986 human chorionic gonadotropin Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000007391 self-medication Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 566846 1987-11-05 1988-05-16 Formules d'hormone de croissance administrees par voie parenterale Expired - Fee Related CA1326439C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11698387A	1987-11-05	1987-11-05
US07/116,983		1987-11-05

Publications (1)

Publication Number	Publication Date
CA1326439C true CA1326439C (fr)	1994-01-25

Family

ID=22370405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 566846 Expired - Fee Related CA1326439C (fr)	1987-11-05	1988-05-16	Formules d'hormone de croissance administrees par voie parenterale

Country Status (3)

Country	Link
AU (1)	AU614551B2 (fr)
CA (1)	CA1326439C (fr)
NZ (1)	NZ226816A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA9711731B (en) *	1996-12-31	1998-07-01	Monsanto Co	Aqueous glycerol formulations of somatotropin

1988
- 1988-05-16 CA CA 566846 patent/CA1326439C/fr not_active Expired - Fee Related
- 1988-11-02 AU AU24621/88A patent/AU614551B2/en not_active Ceased
- 1988-11-02 NZ NZ22681688A patent/NZ226816A/en unknown

Also Published As

Publication number	Publication date
NZ226816A (en)	1991-04-26
AU614551B2 (en)	1991-09-05
AU2462188A (en)	1989-05-11

Legal Events

Date	Code	Title	Description
2004-01-26	MKLA	Lapsed

Publication	Publication Date	Title
US5102870A (en)	1992-04-07	Treatment and prevention of oral mucositis with growth factors
DE69719360T2 (de)	2003-12-04	Zusammensetzungen und methoden zur steigerung der darmfunktion
KR100217258B1 (ko)	1999-09-01	경비조성물
US5968899A (en)	1999-10-19	Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
US5112804A (en)	1992-05-12	Pharmaceutical composition and method of intranasal administration
US10945986B2 (en)	2021-03-16	Treatment for ischemic stroke
EP0308197A2 (fr)	1989-03-22	Méthode pour stimuler le système immunitaire
CA2142455A1 (fr)	1994-03-03	Methode de traitement general des pathologies cataboliques et des blessures aux tissus de l'organisme
US20100330093A1 (en)	2010-12-30	Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
DE69305091T2 (de)	1997-03-13	Methode zur behandlung oder verhütung von fettleibigkeit
JP3848537B2 (ja)	2006-11-22	ドラメクチン製剤
CA1326439C (fr)	1994-01-25	Formules d'hormone de croissance administrees par voie parenterale
HUT74275A (en)	1996-11-28	Process for treatment of rheumatoid arthritis
US7947304B2 (en)	2011-05-24	Human growth hormone patch formulations
EP1079801A1 (fr)	2001-03-07	Formulation pharmaceutique destinee a l'administration par voie nasale
EP0839046B1 (fr)	2002-01-23	Recepteur de tnf et hormone steroidienne dhea en therapie combinee
DE3881254T2 (de)	1993-09-02	Pharmazeutische zusammensetzung.
US20210251886A1 (en)	2021-08-19	Oral mucosal delivery systems comprising monophasic concentrate of teriparatide
US20030092628A1 (en)	2003-05-15	Gonadotropin releasing hormone antagonist
EP1092438B1 (fr)	2006-06-14	Compositions pharmaceutiques contenant des Inhibiteurs de l'hormone de croissance ou leurs fragments biologiquement actifs pour le traitement de myomes utérins
EP0672420A1 (fr)	1995-09-20	Substance guerissant les blessures
US7012060B1 (en)	2006-03-14	TNF receptor and steroid hormone in a combined therapy
JPH07101877A (ja)	1995-04-18	血小板減少症治療剤
KR102494794B1 (ko)	2023-02-03	여성 성기능장애의 치료를 위한 약학 조성물 및 방법
JPS63243033A (ja)	1988-10-07	経鼻投与組成物